Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma

Haematologica

Volumn 99, Issue 11, 2014, Pages e242-e243

  Brioli, Annamaria ^a   Zannetti, Beatrice Anna ^a   Zamagni, Elena ^a   Tacchetti, Paola ^a   Pantani, Lucia ^a   Mancuso, Katia ^a   Pezzi, Annalisa ^a   Rocchi, Serena ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Multiple myeloma; Peripheral neuropathy; Subcutaneous bortezomib

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; TREATMENT RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MULTIPLE MYELOMA;

EID: 84908456353     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.110221     Document Type: Letter

References (14)

1. Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, et al. Subcutaneous bortezomib incorporated into the bortezomib- thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica. 2014;99(3):4.
2. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752-8.
3. Richardson P, Briemberg H, Jagannath S, Wen P, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-20.
4. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau J-L, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-9.
5. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12(5):431-40.
6. Lamm W, Drach-Schauer B, Eder S, Drach J. Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology. 2013;85(4):223-7.
7. Shah G, Kaul E, Fallo S, Cossor F, Smith H, Sprague K, et al. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther. 2013;35(10):1614-20.
8. van den Bent MJ, van Raaij-van den Aarssen VJ, Verweij J, Doorn PA, Sillevis Smitt PA, Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve. 1997;20(6): 750-2.
9. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol. 2012;30(24):2946-55.
10. Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013; 31(2):247-55.
11. Argyriou A, Iconomou G, Kalofonos H. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593-9.
12. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON- 65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057-65.
13. Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics. 2011;21(3):121-9.
14. Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, et al. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study. Am J Hematol. 2014 Aug 27[Epub ahead of print].